The JmjC domain histone H3K36me2/me1 demethylase NDY1/KDM2B is overexpressed in various types of cancer. Here we show that knocking down NDY1 in a set of ten cell lines derived from a broad range of human tumors inhibited their anchorage-dependent and anchorage-independent growth by inducing senescence and/or apoptosis in some and by inhibiting G1 progression in all. We further show that the knockdown of NDY1 in mammary adenocarcinoma cell lines decreased the number, size and replating efficiency of mammospheres and downregulated the stem cell markers ALDH and CD44, while upregulating CD24. These findings combined, suggest that NDY1 is required for the self-renewal of cancer stem cells and are in agreement with additional findings showing that, tumor cells in which NDY1 was knocked down undergo differentiation and a higher number of them is required to induce mammary adenocarcinomas, upon orthotopic injection in animals. Mechanistically, NDY1 functions as a master regulator of a set of microRNAs that target several members of the polycomb complexes PRC1 and PRC2 and its knockdown results in the de-repression of these microRNAs and the downregulation of their polycomb targets. Consistent with these observations, NDY1/KDM2B is expressed at higher levels in basal-like triple negative breast cancers and its overexpression is associated with higher rates of relapse after treatment. In addition, NDY1-regulated microRNAs are downregulated in both normal and cancer mammary stem cells. Finally, in primary human breast cancer, NDY1/KDM2B expression correlates negatively with the expression of the NDY1-regulated microRNAs, and positively with the expression of their PRC targets.
the knockdown of NDY1 in mammary adenocarcinoma cell lines decreased the number, size and replating efficiency of mammospheres and downregulated the stem cell markers ALDH and CD44, while upregulating CD24. These findings combined, suggest that NDY1 is required for the self-renewal of cancer stem cells and are in agreement with additional findings showing that, tumor cells in which NDY1 was knocked down undergo differentiation and a higher number of them is required to induce mammary adenocarcinomas, upon orthotopic injection in animals. Mechanistically, NDY1 functions as a master regulator of a set of microRNAs that target several members of the polycomb complexes PRC1 and PRC2 and its knockdown results in the de-repression of these microRNAs and the downregulation of their polycomb targets. Consistent with these observations, NDY1/KDM2B is expressed at higher levels in basal-like triple negative breast cancers and its overexpression is associated with higher rates of relapse after treatment. In addition, NDY1-regulated microRNAs are downregulated in both normal and cancer mammary stem cells. Finally, in primary human breast cancer, NDY1/KDM2B expression correlates negatively with the expression of the NDY1-regulated microRNAs, and positively with the expression of their PRC targets. 
INTRODUCTION
NDY1/KDM2B is a jumonji domain-containing histone lysine demethylase with specificity against histone H3K36me2/me1 and H3K4me3 (1, 2) . Its involvement in oncogenesis was originally suggested by studies that identified NDY1/KDM2B and its homolog NDY2/KDM2A as targets of provirus integration in retrovirus-induced rodent lymphomas (1) . Subsequently, it was shown that NDY1/KDM2B inhibits replicative senescence and promotes the immortalization and proliferation of mouse embryo fibroblasts (MEFs) in culture (2, 3) . This is due, at least in part, to the repression of the INK4A-INK4B/Arf locus, via the NDY1-dependent coupling of histone H3K36me2/me1 demethylation, with histone H3K27 trimethylation and histone H2AK119 ubiquitination. Mechanistically, it has been shown that the coupling to histone H3K27 trimethylation is mediated by the recruitment of EZH2, the enzymatic subunit of polycomb repressive complex 2 (PRC2) and that the coupling to histone H2AK119 ubiquitination is mediated by the recruitment of polycomb repressive complex 1 (PRC1) (2) . Notably, we recently showed that NDY1/KDM2B is induced by FGF-2 via DYRK1A activation and CREB phosphorylation.
The induced NDY1 binds the miR-101 gene in concert with EZH2, and this results in the repression of miR-101 and the upregulation of its target EZH2. The upregulation of EZH2 reinforces this pathway and locks the cells in a state characterized by the overexpression of both NDY1 and EZH2. One type of human cancer where EZH2 is overexpressed, often via the activation of the FGF-2-NDY1-miR-101-EZH2 axis is bladder cancer (4) . Other recent studies have also shown that NDY1/KDM2B binds CpG islands (CGIs) via its CXXC motif and recruits PRC1, which catalyzes histone H2AK119 ubiquitination (1, 2, (5) (6) (7) . Consistent with these observations, NDY1/KDM2B facilitates on April 14, 2017. © 2014 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on ; DOI: 10.1158/0008-5472. CAN-13-2733 stem cell reprogramming of differentiated cells in culture (1, 8, 9) and protects cells from oxidative stress and ROS-induced DNA damage by regulating the expression of antioxidant genes (2, 3, 10) . Finally, it is expressed at high levels in various types of stem cells and its expression declines with differentiation (2,6) The preceding data, combined with observations showing that NDY1 is overexpressed in human T-cell and B-cell acute lymphoblastic leukemia (T-ALL and B-ALL), acute myeloid leukemias (AML) (4,11), seminomas (12) and mammary (13, 14) and pancreatic adenocarcinomas (15) , strongly suggest that NDY1 functions as an oncogene.
In the present study, we knocked down NDY1 in a set of ten cell lines derived from a broad range of human tumors. In all these cell lines, the NDY1 knockdown consistently induced G1 delay and senescence and/or apoptosis and interfered with anchoragedependent and anchorage-independent growth. Focusing in a set of two basal-like and two luminal mammary adenocarcinoma cell lines, we showed that the knockdown of 5 function in this pathway, they cannot rescue the defect induced by the loss of NDY1, which functions as the master regulator of PRC1 and PRC2 by integrating the activities of these complexes. Consistent with these observations, NDY1/KDM2B is expressed at higher levels in basal-like than in luminal mammary adenocarcinomas and its expression is associated with higher rates of relapse after treatment. More important, NDY1-regulated microRNAs are expressed at low levels in normal and neoplastic mammary stem cells, and their expression correlates negatively with the expression of NDY1/KDM2B, as well as the expression of their polycomb targets.
MATERIALS AND METHODS
Detailed descriptions of the materials and the methods are presented in the supplement.
Cell culture
Cancer cell culture conditions as well as pre-miRs and anti-miRs are listed in supplemental materials and methods. SKOV3, OVCAR3 and OVCAR4 cell lines were kindly provided by Dr Athan Kuliopulos and SUM159 cells by Dr Stephen Ethier. All other cell lines were obtained from ATCC. The authors carried out no additional authentication within the last 6 months. Retroviral and lentiviral packaging and infections were carried out using standard methods. Cell proliferation was measured with the MTT assay. Soft agar and sphere formation assays were performed as previously described (4, 16) . All studies with cancer cell lines were limited to established cell lines. Patientderived cell lines were not employed. 6 RNA isolation and real time RT-PCR were carried using standard procedures. The miRNA levels were normalized based on U6 small nuclear RNA (internal controls). The mRNA levels were normalized based on GAPDH or 18S rRNA (internal control).
Real-time RT-PCR for miRNAs and mRNAs

Western blotting
Total cell lysates were generated using a Triton X-100 lysis buffer. Western blots of cell lysates resolved by SDS-PAGE were probed with the antibodies listed in the supplement.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using the Chromatin Immunoprecipitation assay kit (Millipore, cat no. 17-295).
Cell cycle distribution of proliferating cells, apoptosis and differentiation markers
Cell cycle distribution was determined as previously described (10) . Apoptosis was measured by Annexin V staining and flow-cytometry (BD Pharmigen, cat no 556419) and/or by the Caspase-Glo ® 3/7 Assay (Promega, cat no. G8091). Cells stained for CD24-FITC/EpCAM-PE/CD49f-APC, or ALDH activity (ALDEFLUOR StemCell Technologies, cat no. 01700) (CD24-FITC/CD44-APC were also analyzed by flowcytometry. Data on the expression of NDY1/KDM2B in different types of breast cancer and the rates of relapse after treatment were calculated from the study GSE19783 (18) .
Orthotopic mammary adenocarcinoma xenografts
Significance of differences in the rate of recurrence in patients with NDY1/KDM2B high and low tumors was calculated with the Gehan-Breslow-Wilcoxon test. Finally, the correlations between the expression of NDY1, the NDY1-regulated microRNAs and their polycomb targets were made using RNA isolated from a set of 16 primary human breast cancer specimens (Table S5 ). The significance of the correlation between the expression of NDY1 and NDY1-regulated microRNAs, as well as between NDY1 and the genes encoding members of the polycomb complexes in these tumors, was calculated using the Pearson statistical test. Due to the small size of the tumor samples, gene expression was examined only at the RNA level. Tumors were obtained from the Tufts Cancer Center tissue bank, following IRB approval (for details see Table S5 ).
Replicates and statistical analysis
All experiments were performed three times and the data are presented as mean ± SD unless otherwise stated. Two-group comparisons were performed with the Student's ttest and p-values of 0.05 or less were considered significant (*** p<0.001, ** 0.001<p<0.01, * 0.01<p<0.05). suggesting that NDY1/KDM2B is pro-tumorigenic (19) . Four of the cell lines were of mammary epithelial origin and of these two were basal-like (MDAMB-23 and SUM159) and two luminal (T47D and MCF7). Since our focus is on breast cancer, further studies were carried out using these cell lines.
To address the mechanism responsible for the effects of the knockdown on the accumulation of live cells in culture, we first asked whether knocking down NDY1/KDM2B interferes with cell cycle progression. Flow-cytometry of EtBr-stained semi-confluent cell cultures growing under normal tissue culture conditions, revealed that the knockdown of NDY1 induces a partial G1 arrest in all the cell lines ( Fig 1C, Fig   S1D) , and suggested that NDY1 contributes to progression from G1 to S.
The knockdown of NDY1 may interfere with the accumulation of live cells in culture also by promoting senescence or apoptosis. In agreement with our earlier observations in MEFs (1), light microscopy of semi-confluent monolayers, stained for β-galactosidase, revealed that the knockdown elicits a strong senescence-phenotype, which however is limited to T47D cells (68% β-gal-positive) (Fig 1D) . Flow-cytometery of Annexin V-9 stained MDAMB-231-shNDY1, MCF7-shNDY1 and T47D-shNDY1 cells, and their shRNA Controls, revealed that shNDY1 promotes apoptosis, primarily in the first two cell lines ( Fig 1E) . We conclude that whereas the knockdown of NDY1 inhibits G1 progression in all the tumor cell lines we examined, its ability to induce senescence and apoptosis is selective.
The preceding data addressed the role of NDY1/KDM2B in transformed cells. To determine whether NDY1 is also required for the initiation of transformation, we transduced MCF-10A cells, an immortalized but not transformed mammary epithelial cell line, with shNDY1 or shRNA-control lentiviral constructs and we superinfected them with an H-Ras-V12 retrovirus. Of these cells, only the shControls superinfected with H-Ras-V12 formed colonies in soft agar (Fig S2A and S2B ). Cell cycle analysis of sub-confluent monolayer cultures of the same cells showed that the shNDY1 cells accumulate in G1 (Fig S2C) . Finally, whereas shRNA control cells transduced with the H-Ras-V12 retrovirus formed mammospheres when cultured in suspension, the shNDY1 cells did not ( Fig S2D) . These findings combined show that NDY1 is required not only for the maintenance, but also for the initiation of the cell transformation phenotype.
NDY1/KDM2B is required for the maintenance of the cancer stem cell population.
Tumor cell lines contain populations of cells that possess tumor-initiating properties.
These cells tend to form spheres when grown in suspension in defined serum-free media and they are known as tumor initiating, or cancer stem cells (for Review see (20)).
Tumor initiating cells in mammary carcinoma cell lines form mammospheres (16, 21) . an shNDY1 lentiviral construct gave rise to fewer and smaller mammospheres than similarly cultured shRNA-control cells (Fig 2A-C) . This suggests that NDY1 is required for the maintenance of tumor initiating cells, as well as for their proliferation in the mammosphere environment. Re-culturing cells harvested from mammospheres of two of the cell lines (MDAMB-231 and MCF7), revealed that the difference of shNDY1 and shRNA-control cells in mammosphere-forming potential increases with passage ( Fig   S3A) , suggesting that NDY1 is also required for the long-term maintenance of the tumor initiating phenotype. Flow-cytometric two-color analysis for CD49f/EpCAM or CD49f/CD24, revealed that the knockdown of NDY1 promotes the downregulation of CD49f in concert with the upregulation of EpCAM and CD24 (Fig 3A) . Single color analysis of the same cells confirmed the preceding results (Fig S4A) . These results suggest that NDY1/KDM2B is essential for the maintenance of the basal/myoepithelial/luminal progenitor cell phenotype. This suggestion is supported by the results in Fig 3B, which show that whereas the basal markers CD10, NOTCH4 and CK14 (25) are dramatically downregulated in shNDY1-transduced cells, the luminal markers CK18, CK19 and GATA3 (25) are upregulated.
In parallel experiments, two color and single color analyses of MCF7 and T47D cells transduced with shNDY1 or shRNA-control constructs also showed that shNDY1 downregulates CD49f and upregulates CD24 (Fig S4B and S4C) . The knockdown of NDY1 in these cells promoted the upregulation of GATA3, CK18 and CK19, as in MDAMB-231 and SUM159 cells. However, it also promoted the upregulation rather than CAN-13-2733 the downregulation of NOTCH4 and CD10 (Fig S4D) . This suggests that NDY1 may be required for the maintenance of both the basal and the luminal differentiation state.
The hypothesis that NDY1/KDM2B may be expressed at higher levels in basal-like versus luminal breast cancer, which was suggested by the preceding data, was confirmed by comparing its expression in basal-like vs all other types of human mammary adenocarcinomas in the study GSE19783 (18) (Fig S4E) . Infection of shNDY1-transduced T47D cells with a murine NDY1/KDM2B retroviral construct restored NDY1/KDM2B expression (Fig S5A) . The biological outcome of this rescue experiment was the restoration of cell proliferation (Fig S5B) , cell cycle progression (Fig S5C) , growth in soft agar (Fig S5D, S5E) , mammosphere formation (Fig S5F, S5G ) and CD24 expression (Fig S5H) . These findings confirmed that the shNDY1 phenotype is due to the knockdown of NDY1/KDM2B and not to off-target effects of shNDY1. 
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The preceding experiments suggested that NDY1/KDM2B regulates cancer stem cell self-renewal and differentiation. Probing western blots of shNDY1 or shRNA-control MDAMB-231, MCF7 and T47D cells with antibodies against a panel of PRC1 and PRC2 subunits, revealed that the knockdown of NDY1 downregulates the PRC2 subunits EZH2 and SUZ12, but not EED, and the PRC1 subunits BMI1 and RING1B (Fig 4A) .
Given the function of PRC1 and PRC2 (for Review see (28) (29) (30) ), these data provide potential mechanistic support to the hypothesis that NDY1 regulates cancer stem cell self renewal. In agreement with these results, knocking down NDY1 induced the expression of p21CIP1, a known target of PRC1 (31), and RUNX3, WNT1, HOXA4 and PLCβ4, known targets of PRC2 (32) (Fig 4B) . The up-regulation of WNT1 was surprising, because WNT signaling has been linked to stem cell self-renewal (for Review see (33) . However, additional experiments showed that despite the upregulation of Wnt1, the knockdown of NDY1 inhibited the Wnt pathway, probably because of changes in other regulators of Wnt signaling (Fig S6) .
We had previously shown that the upregulation of NDY1 activates an EZH2/miR-101 switch, which ultimately locks the cells in a developmental state characterized by high EZH2 and low miR-101 (4). We therefore hypothesized that shNDY1 may downregulate EZH2 by reversing this pathway. We also hypothesized that it may downregulate SUZ12, BMI1 and RING1B by similar mechanisms. Measuring the expression of a set of microRNAs that target the subunits of PRC1 and PRC2 listed above (34, 35) genes encoding all these microRNAs, in concert with EZH2. Parallel ChIP experiments showed that whereas EZH2 binds, NDY1 does not bind the promoter region of proteincoding genes that are also repressed by NDY1 via EZH2, such as ADRB2 and WNT1 (Fig 4D) .
Superinfection of shNDY1-transduced MDAMB-231 cells with retroviral constructs of EZH2 or BMI1 failed to rescue the defects in monolayer growth, colony formation in soft agar and mammosphere formation, induced by the NDY1/KDM2B knockdown (Fig S7   and S8 ). In agreement with these results, EZH2 also failed to increase the binding of NDY1/KDM2B and EZH2 to the PRC1 and PRC2-targeting microRNAs that were derepressed by the NDY1 knockdown (Fig S7E, Left and middle panels) and as a result, it failed to repress these microRNAs (Fig S7E, Right panel) and. These results are consistent with the hypothesis that the binding of EZH2 correlates with histone blots of cell lysates probed with the indicated antibodies, confirmed that whereas the pre-miRs upregulate EZH2, SUZ12, BMI1 and RING1B, the anti-miRs downregulate them (Fig 5A) . We conclude that the de-repression of these miRs in shNDY1 MDAMB-231 cells is responsible for the down-regulation of the PRC1 and PRC2 subunits.
Pre-miR expression in shControl cells enhanced, while anti-miR expression in shNDY1 cells inhibited the activation of caspases 3 and 7 (Fig 5B) . Moreover, pre-miRs inhibited, while anti-miRs enhanced cell proliferation in the same cells (Fig 5C) . Finally, the premiRs reproduced partially the NDY1/KDM2B knockdown phenotype on the expression of the stem cell markers CD44 and ALDH1 in shControl cells, while the anti-miRs partially blocked the NDY1 knockdown phenotype in shND1 cells (Fig 5D, 5E) . We conclude that NDY1/KDM2B plays an obligatory role in the regulation of miR-101, miR-181, miR-200b and miR-203 and that PRC1 and PRC2, which are under the direct control of these microRNAs, function as critical effectors of tumor cell survival, proliferation, stem cell maintenance and differentiation.
Loss of NDY1/KDM2B inhibits growth, depletes the stem cell compartment and promotes differentiation of cancer cells in an orthotopic model of breast cancer.
To determine the effects of shNDY1 in vivo, shNDY1 and shControl-transduced MDAMB-231 cells were inoculated into the mammary gland of NOD/SCID mice.
Monitoring tumor growth for up to 70 days post-injection, revealed that the growth of cells transduced with the shNDY1 construct was significantly delayed (Fig 6A-6C (Fig 7) . The p value of some of the comparisons was smaller than 0.1, but higher than 0.05. Given the small number of samples and the consistency in the directionality of the data, we believe that even these not formally significant data, are borderline significant. Here we wish to point out that, due to the small size of the tumor samples, the expression of the polycomb targets of the microRNAs regulated by NDY1/KDM2B was examined only at the RNA level. However, given that the same microRNAs regulate their polycomb targets at the RNA level in tumor cell lines in culture, we suggest that the observed microRNA/mRNA correlations are likely to reflect similar miroRNA/protein correlations.
DISCUSSION
Earlier studies had shown that NDY1/KDM2B functions as an oncogene in retrovirusinduced rodent T cell lymphomas (1) . In addition, they provided evidence that NDY1 functions as an oncogene in human bladder and pancreatic carcinomas (4, 15) . 
Mechanistically, these activities of NDY1 depend on the concerted action of NDY1 and EZH2, which results in the repression of a set of microRNAs that target multiple subunits of PRC1 and PRC2.
The NDY1/EZH2/microRNA/PRC axis was originally observed and experimentallyvalidated in established breast cancer cell lines. Even though patient-derived cancer cell lines were not utilized in this study, the relevance of this axis to human breast cancer was confirmed by observations that in primary tumors, the expression of NDY1/KDM2B exhibits a negative correlation with the expression of the NDY1-regulated microRNAs and a positive correlation with the expression of their polycomb targets. Of the microRNA targets of NDY1/EZH2, which were interrogated in this paper, the members of the miR-200 family had been shown previously to be expressed at low levels in normal human and mouse mammary stem cells and in breast cancer stem cells isolated from primary human breast cancer specimens (35, 36) . These data support the role of NDY1/KDM2B in stem cell self-renewal, in vivo. Further support for the essential role of NDY1 in stem cell biology in vivo was provided by the preliminary analysis of an RNASeq experiment in shControl and shNDY1-transduced T47D cells. This analysis, which will be presented in full elsewhere, showed that NDY1 also represses miR-141, a member of the miR-200c cluster, and all the members of the miR-182/96/193 cluster (data not shown), which are also expressed at low levels in the normal and neoplastic mammary stem cells (36) . NDY1/KDM2B regulates PRC1 and PRC2 at multiple levels. Data presented in this report showed that NDY1/KDM2B functions in concert with EZH2 to repress a set of microRNAs that target multiple subunits of both PRC1 and PRC2. Equally important, the CAN-13-2733 overexpression of EZH2 or BMI1, both of which were downregulated in shNDY1-transduced cells, failed to restore the phenotype in NDY1 knockdown cells. This finding is consistent with additional observations showing that EZH2 overexpression is not sufficient to repress at least some of its microRNA targets and that catalytically active NDY1 is required to activate the repressive function of EZH2. We conclude that NDY1 functions as a master regulator of both PRC1 and PRC2. In summary, data presented in this report, identify a novel microRNA-dependent mechanism by which NDY1/KDM2B regulates PRC1 and PRC2 and they show that through this mechanism NDY1/KDM2B regulates the self-renewal and differentiation of tumor initiating cells in human breast cancer cell lines. These data confirm the importance of NDY1/KDM2B as a therapeutic target for breast and perhaps other human cancers. 
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